$SSKN
STRATA Skin Sciences, Inc.

2020 Q2 Form 10-Q Financial Statement

#000105151420000037 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $4.030M $7.725M
YoY Change -47.83% 4.56%
Cost Of Revenue $2.066M $2.815M
YoY Change -26.61% -20.68%
Gross Profit $1.964M $4.910M
YoY Change -60.0% 27.9%
Gross Profit Margin 48.73% 63.56%
Selling, General & Admin $3.332M $5.658M
YoY Change -41.11% 18.15%
% of Gross Profit 169.65% 115.23%
Research & Development $247.0K $235.0K
YoY Change 5.11% -12.64%
% of Gross Profit 12.58% 4.79%
Depreciation & Amortization $495.0K $691.0K
YoY Change -28.36% -25.38%
% of Gross Profit 25.2% 14.07%
Operating Expenses $3.579M $5.893M
YoY Change -39.27% 16.51%
Operating Profit -$1.615M -$983.0K
YoY Change 64.29% -19.36%
Interest Expense -$20.00K $145.0K
YoY Change -113.79% -55.79%
% of Operating Profit
Other Income/Expense, Net -$18.00K -$145.0K
YoY Change -87.59% -60.81%
Pretax Income -$1.633M -$1.128M
YoY Change 44.77% -29.01%
Income Tax $47.00K -$46.00K
% Of Pretax Income
Net Earnings -$1.680M -$1.082M
YoY Change 55.27% -33.58%
Net Earnings / Revenue -41.69% -14.01%
Basic Earnings Per Share -$0.05 -$0.03
Diluted Earnings Per Share -$0.05 -$0.03
COMMON SHARES
Basic Shares Outstanding 33.73M 31.36M
Diluted Shares Outstanding 33.73M 31.36M

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.23M $15.94M
YoY Change -29.55% 10.31%
Cash & Equivalents $11.23M $15.94M
Short-Term Investments
Other Short-Term Assets $7.830M $630.0K
YoY Change 1142.86% -24.1%
Inventory $3.470M $3.607M
Prepaid Expenses
Receivables $1.361M $3.476M
Other Receivables $0.00 $0.00
Total Short-Term Assets $23.89M $23.65M
YoY Change 0.99% 16.75%
LONG-TERM ASSETS
Property, Plant & Equipment $4.999M $4.789M
YoY Change 4.39% -23.63%
Goodwill $8.803M $8.803M
YoY Change 0.0% 0.0%
Intangibles $7.050M $8.860M
YoY Change -20.43% -16.96%
Long-Term Investments
YoY Change
Other Assets $314.0K $376.0K
YoY Change -16.49% 683.33%
Total Long-Term Assets $22.32M $24.31M
YoY Change -8.19% -5.73%
TOTAL ASSETS
Total Short-Term Assets $23.89M $23.65M
Total Long-Term Assets $22.32M $24.31M
Total Assets $46.21M $47.97M
YoY Change -3.66% 4.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.451M $2.091M
YoY Change 17.22% 41.57%
Accrued Expenses $4.703M $4.748M
YoY Change -0.95% 26.48%
Deferred Revenue $1.020M $2.292M
YoY Change -55.5% 27.19%
Short-Term Debt $7.280M $0.00
YoY Change -100.0%
Long-Term Debt Due $799.0K $1.767M
YoY Change -54.78%
Total Short-Term Liabilities $16.60M $11.14M
YoY Change 49.06% 57.21%
LONG-TERM LIABILITIES
Long-Term Debt $1.729M $5.699M
YoY Change -69.66% -22.16%
Other Long-Term Liabilities $71.00K $383.0K
YoY Change -81.46% 32.99%
Total Long-Term Liabilities $1.800M $6.082M
YoY Change -70.4% -20.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.60M $11.14M
Total Long-Term Liabilities $1.800M $6.082M
Total Liabilities $19.43M $18.51M
YoY Change 4.99% 19.8%
SHAREHOLDERS EQUITY
Retained Earnings -$217.3M -$213.2M
YoY Change 1.92% 2.44%
Common Stock $34.00K $33.00K
YoY Change 3.03% 10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.78M $29.46M
YoY Change
Total Liabilities & Shareholders Equity $46.21M $47.97M
YoY Change -3.66% 4.16%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$1.680M -$1.082M
YoY Change 55.27% -33.58%
Depreciation, Depletion And Amortization $495.0K $691.0K
YoY Change -28.36% -25.38%
Cash From Operating Activities $600.0K $70.00K
YoY Change 757.14% -153.85%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K -$520.0K
YoY Change -75.0% 1.96%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$130.0K -$520.0K
YoY Change -75.0% 4.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.530M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 600.0K 70.00K
Cash From Investing Activities -130.0K -520.0K
Cash From Financing Activities 2.530M 0.000
Net Change In Cash 3.000M -450.0K
YoY Change -766.67% -104.08%
FREE CASH FLOW
Cash From Operating Activities $600.0K $70.00K
Capital Expenditures -$130.0K -$520.0K
Free Cash Flow $730.0K $590.0K
YoY Change 23.73% 55.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2451000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5791899
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6511321
CY2020Q2 us-gaap Assets
Assets
46210000
CY2019Q4 us-gaap Assets
Assets
47343000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1880000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1361000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4386000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4703000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5134000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16960000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15962000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
244020000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
243180000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
323000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
303000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
430000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
410000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
256000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
184000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
57000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
453000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
452000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
905000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
905000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12000
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5756838
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6339848
CY2020Q2 us-gaap Assets Current
AssetsCurrent
23889000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
23555000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11231000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8129000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15941000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2999000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-546000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15629000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16487000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18628000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15941000
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.75
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
149901
CY2020Q2 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
600000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7955000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33754909
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32932273
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33754909
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32932273
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
34000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
33000
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1020000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2832000
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
53000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
110000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
51000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
2066000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
2815000
us-gaap Cost Of Revenue
CostOfRevenue
4397000
us-gaap Cost Of Revenue
CostOfRevenue
5689000
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
135000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
135000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-89000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
495000
CY2019Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
691000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1081000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1442000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1986000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2347000
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2010000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1000000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1193000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
705000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1410000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7050000
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16100000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1410000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1410000
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9050000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1410000
CY2020Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
705000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-19000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-22000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1890000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2700000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3992000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5180000
CY2020Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q2 us-gaap Goodwill
Goodwill
8803000
CY2019Q4 us-gaap Goodwill
Goodwill
8803000
CY2020Q2 us-gaap Gross Profit
GrossProfit
1964000
CY2019Q2 us-gaap Gross Profit
GrossProfit
4910000
us-gaap Gross Profit
GrossProfit
6363000
us-gaap Gross Profit
GrossProfit
9519000
us-gaap Income Tax Examination Estimate Of Possible Loss
IncomeTaxExaminationEstimateOfPossibleLoss
801000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1633000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1128000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2580000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2504000
CY2020Q2 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
171000
CY2020Q2 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
720000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-46000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
135000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-89000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1812000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
193000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
571000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
327000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2953000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
85000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-431000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
248000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
443000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
813000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-107000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-116000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
42000
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7050000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
234000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
228000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
186000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1483000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
371000
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18000
CY2019Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-145000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-17000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-280000
us-gaap Interest Paid Net
InterestPaidNet
103000
us-gaap Interest Paid Net
InterestPaidNet
404000
CY2020Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
714000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
376000
CY2020Q2 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2756000
CY2019Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2651000
CY2020Q2 us-gaap Inventory Net
InventoryNet
3470000
CY2019Q4 us-gaap Inventory Net
InventoryNet
3027000
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
242000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
456000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46210000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47343000
CY2020Q2 us-gaap Liabilities
Liabilities
19432000
CY2019Q4 us-gaap Liabilities
Liabilities
18690000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16601000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17434000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
2528000
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1729000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
799000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1201000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
406000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1680000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1082000
us-gaap Net Income Loss
NetIncomeLoss
-2715000
us-gaap Net Income Loss
NetIncomeLoss
-2415000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1078000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
353000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
3579000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
5893000
us-gaap Operating Expenses
OperatingExpenses
8926000
us-gaap Operating Expenses
OperatingExpenses
11743000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
112000
us-gaap Operating Lease Cost
OperatingLeaseCost
224000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
116000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1333000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1035000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-730000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-952000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2528000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-145000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
114000
us-gaap Operating Lease Payments
OperatingLeasePayments
207000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
110000
us-gaap Operating Lease Payments
OperatingLeasePayments
204000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1249000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
896000
us-gaap Operating Lease Cost
OperatingLeaseCost
227000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1155000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1314000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
159000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
147000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1615000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-983000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2563000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2224000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
314000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
347000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
71000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
178000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2103
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2103
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
430000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
513000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-weight: bold;">Reclassifications</div><div style="text-align: justify;">Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company&#8217;s equity, results of operations, or cash flows.</div></div>
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2528000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
119000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
170000
CY2019Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
194000
CY2020Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
48000
CY2019Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
56000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
102000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
90000
CY2020Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
181000
CY2019Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
272000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
232000
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
238000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
139000
CY2019Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
291000
CY2020Q2 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
6000
CY2019Q2 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
75000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
9000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
143000
CY2020Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
20000
CY2019Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
97000
sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
730000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21959000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21331000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4999000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5369000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
72000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
247000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
235000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
539000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
539000
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
7397000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7500000
CY2019Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217276000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214561000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4030000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7725000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10760000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15208000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
214000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
163000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P0Y11M19D
CY2020Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3097000
CY2019Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3193000
sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-26.66
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1442000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2958000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4395000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6024000
us-gaap Share Based Compensation
ShareBasedCompensation
840000
us-gaap Share Based Compensation
ShareBasedCompensation
626000
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
410000
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
303000
CY2020Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7275000
CY2019Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7275000
dei Amendment Flag
AmendmentFlag
false
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
26778000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
28653000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
31248000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
30238000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
29459000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
28048000
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-weight: bold;">Use of Estimates</div><div style="text-align: justify;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of June 30, 2020, the more significant estimates include (1) revenue recognition, in regards to deferred revenues and the contract term and valuation allowances of accounts receivable, (2) the inputs used in the impairment analyses of goodwill, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets, (6) the inventory reserves, (7) state sales and use tax accruals and (8) warranty claims.</div><div>&#160;</div><div style="text-align: justify;">Additionally, the full impact of the COVID-19 outbreak is unknown and cannot be reasonably estimated. However, management has made appropriate accounting estimates on certain accounting matters, which include the allowance for doubtful accounts, inventory valuation, carrying value of the goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company&#8217;s future assessment of the magnitude and duration of the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company&#8217;s financial statements in future reporting periods.</div></div>
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33731739
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31359104
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33448030
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31033114
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33731739
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31359104
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33448030
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31033114
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
STRATA Skin Sciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001051514
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33754909
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
sskn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-142000
sskn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-126000
sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
947000
sskn Increase Decrease Of Lease Liabilities Arising From Obtaining Right Of Use Assets
IncreaseDecreaseOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
sskn Increase Decrease Of Lease Liabilities Arising From Obtaining Right Of Use Assets
IncreaseDecreaseOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
1632000
CY2020Q2 sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
0
CY2019Q2 sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-11.94
sskn Earnings Per Share Basic And Diluted Preferred Share
EarningsPerShareBasicAndDilutedPreferredShare
-29.93
CY2020Q2 sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
0
CY2019Q2 sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
6250
sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
740
sskn Weighted Average Number Of Share Outstanding Basic And Diluted Preferred Stock
WeightedAverageNumberOfShareOutstandingBasicAndDilutedPreferredStock
7093
CY2020Q2 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
163000
CY2020Q2 sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-86000
CY2019Q2 sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-177000
sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-254000
sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-332000
CY2019Q1 sskn Conversion Of Convertible Preferred Stock Amount
ConversionOfConvertiblePreferredStockAmount
0
CY2019Q2 sskn Conversion Of Convertible Preferred Stock Amount
ConversionOfConvertiblePreferredStockAmount
0
CY2020Q1 sskn Conversion Of Convertible Preferred Stock Amount
ConversionOfConvertiblePreferredStockAmount
0
sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.0976
CY2020Q2 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
487000
CY2019Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
578000
CY2020Q2 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.4870
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.5910
CY2019Q2 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.6360
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.6260
CY2020Q2 sskn Delayed Payment To Vendors
DelayedPaymentToVendors
781000

Files In Submission

Name View Source Status
0001051514-20-000037-index-headers.html Edgar Link pending
0001051514-20-000037-index.html Edgar Link pending
0001051514-20-000037.txt Edgar Link pending
0001051514-20-000037-xbrl.zip Edgar Link pending
ex_31-1.htm Edgar Link pending
ex_31-2.htm Edgar Link pending
ex_32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form_10-q.htm Edgar Link pending
image00001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sskn-20200630.xml Edgar Link completed
sskn-20200630.xsd Edgar Link pending
sskn-20200630_cal.xml Edgar Link unprocessable
sskn-20200630_def.xml Edgar Link unprocessable
sskn-20200630_lab.xml Edgar Link unprocessable
sskn-20200630_pre.xml Edgar Link unprocessable